Jim Simons
ARQT icon

Jim Simons’s Arcutis Biotherapeutics ARQT Stock Holding History

Jim Simons’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Sell
58,399
-382,600
-87% -$8.91M ﹤0.01% 2110
2026
Q1 		$10.4M Buy
440,999
+167,000
+61% +$4.26M 0.02% 948
2025
Q4 		$7.96M Buy
+273,999
New +$7.01M 0.01% 1038
2025
Q2 		– Sell
-21,799
Closed -$341K – 3544
2025
Q1 		$341K Buy
21,799
+10,700
+96% +$151K ﹤0.01% 2881
2024
Q4 		$155K Sell
11,099
-181,000
-94% -$1.98M ﹤0.01% 3222
2024
Q3 		$1.79M Buy
+192,099
New +$1.9M ﹤0.01% 2098
2024
Q1 		– Sell
-395,100
Closed -$1.28M – 3689
2023
Q4 		$1.28M Buy
+395,100
New +$1.07M ﹤0.01% 2242
2022
Q4 		– Sell
-65,000
Closed -$1.24M – 4099
2022
Q3 		$1.24M Buy
65,000
+54,200
+502% +$1.23M ﹤0.01% 2366
2022
Q2 		$230K Buy
+10,800
New +$222K ﹤0.01% 3584
2020
Q3 		– Sell
-27,700
Closed -$838K – 3359
2020
Q2 		$838K Buy
+27,700
New +$801K ﹤0.01% 2634

Other funds holding ARQT

Suvretta Capital Management
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Jim Simons's ARQT Position: Q2 2026 in Review

Jim Simons reduced its Arcutis Biotherapeutics (ARQT) stake by 87% in Q2 2026, selling an estimated $8.91M and leaving 58,399 shares worth $1.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2110.

Jim Simons first reported a position in ARQT in Q2 2020 and has held it in 10 quarters since. The position peaked at $10.4M in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Jim Simons held 58,399 shares of Arcutis Biotherapeutics worth $1.53M as of Q2 2026.
  • Jim Simons sold 382,600 Arcutis Biotherapeutics shares in Q2 2026, an estimated $8.91M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #2110 holding.
  • Jim Simons first reported a position in Arcutis Biotherapeutics in Q2 2020 and has held it in 10 quarters since.
  • Jim Simons's Arcutis Biotherapeutics position peaked at $10.4M in Q1 2026.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.